Asthma treating pharmaceutical composition

The present invention relates to an asthma treating pharmaceutical composition, which comprises a compound and any one or a variety of pharmaceutically acceptable carriers. The invention further discloses uses of the compound in preparation of asthma treating drugs, wherein the compound can be prepared in any one pharmaceutically acceptable preparation. According to the present invention, the asthma treating pharmaceutical composition can reduce the high-level expression of IL-17, IL-6, TNF-alpha and TGF-beta in pulmonary alveoli due to allergic asthma, can improve the pathological changes oflung tissue to a certain extent, and has a certain anti-inflammatory and anti-pulmonary fibrosis effect so as to achieve the purpose of asthma treating drugs. 本发明涉及种治疗哮喘的药物组合物，所述药物组合物包含本发明所述化合物和任何种或多种药学上可接受的载体。本发明还公开了本发明所述化合物在制备治疗哮喘的药物中的用途，并且所述化合物可以制备成任何种药学上可接受的制剂形式。本发明药物可以降低因过敏性哮喘而导致的肺泡中高水平IL-17、IL-6、TNF-α及TGF-β的表达，并在定程度上改善肺组织病变情况，具有定的抗炎和抗肺组织纤维化作用，达到治疗哮喘的药物目的。